The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects since splitting off its consumer business earlier this year have been boosted by clinical trial success, though concerns around U.S. litigation over heartburn drug Zantac have spooked investors. GSK shares hit a 2-1/2 month high of 1,470.2 pence in early trade on Wednesday, but were down 0.7% late afternoon, hitting their lowest point in the session. GSK's strong third quarter was somewhat expected, which could explain why the stock is not reacting strongly, Barclays (LON: BARC ) analyst Emily Field told Reuters, highlighting that the Zantac overhang makes it difficult for new investors to get involved.